论文部分内容阅读
首次进入期效力试验的1型HIV(HIV-1)疫苗,虽未能产生有效的免疫保护作用,但评价过程本身却留给我们诸多经验和教训。对今后HIV-1疫苗的临床研究提出了新的问题和挑战,包括如何研制能诱导广谱中和抗体的疫苗;如何将基础研究的成果及时应用于疫苗开发中;如何实现科学家之间的理解和合作;如何加强与媒体的交流,将科研成果准确、清楚地解释给民众。
The HIV-1 vaccine of the first entry-phase efficacy trial failed to produce an effective immunoprotective effect, but the evaluation process itself left us with much experience and lessons. The clinical research on HIV-1 vaccine in the future poses new problems and challenges, including how to develop a vaccine that can induce broad-spectrum neutralizing antibodies, how to timely apply basic research results to vaccine development, and how to understand scientists And cooperation; how to strengthen exchanges with the media, the scientific research results accurately and clearly explained to the people.